ANTENGENE-B(06996),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06996 ANTENGENE-B

Not Yet Opened 09-22 16:08:13

3.540

-0.045

-1.26%

High3.665	Low3.500	Vol1.16M
Open3.585	D1 Closing3.585	Amplitude4.60%
Mkt Cap2.44B	Tradable Cap2.44B	Total Shares688.00M
T/O4.13M	T/O Rate0.17%	Tradable Shares688.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"ANTENGENE-B","latestPrice":3.54,"timestamp":1790064493008,"preClose":3.585,"halted":0,"volume":1161500,"delay":0,"changeRate":-0.012552301255230106,"floatShares":688000000,"shares":688000000,"eps":-0.44495132913427826,"marketStatus":"Not Yet Opened","change":-0.045,"latestTime":"09-22 16:08:13","open":3.585,"high":3.665,"low":3.5,"amount":4129662,"amplitude":0.046025,"askPrice":3.63,"askSize":10000,"bidPrice":3.54,"bidSize":18500,"shortable":3,"etf":0,"ttmEps":0.09847592560926825,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790127000000},"marketStatusCode":0,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":3.585,"openAndCloseTimeList":[[1790040600000,1790049600000],[1790053200000,1790064000000]],"volumeRatio":1.116076,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996/tweets","defaultTab":"tweets","newsList":[{"id":"1197407077","title":"Antengene Executes HKD 17,200 On-Exchange Share Buyback, Adds 5,000 Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1197407077","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197407077?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:23","pubTimestamp":1789989797,"startTime":"0","endTime":"0","summary":"Antengene Corporation Limited reported a minor adjustment to its share capital following an on-exchange repurchase executed on 21 September 2026. Key details are as follows: • Transaction overview:...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138612075","title":"Antengene-B Surges Over 9% as Pivotal Phase III CLINCH-3 Trial Completes First Patient Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=1138612075","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138612075?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:18","pubTimestamp":1789975093,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) saw its shares climb more than 9% in Hong Kong trading, with the stock last up 9.06% at HK$3.61, on turnover of HK$3.84 million. According to the company's official WeChat...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","VXUS","BK1191","BK1583","KCAI","BK4585","BK4588","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669332801","title":"Antengene Doses First Patient in Phase III Clinch-3 Trial of ATG-022 for Cldn18.2+ Gastric, GEJ Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669332801","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669332801?lang=en_us&edition=fundamental","pubTime":"2026-09-21 08:30","pubTimestamp":1789950623,"startTime":"0","endTime":"0","summary":"Antengene doses first patient in Phase III CLINCH-3 trial of ATG-022 for CLDN18.2+ gastric, GEJ cancerAntengene dosed the first patient in China in the pivotal Phase III CLINCH-3 trial of ATG-022 for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2rgfTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1583","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669281133","title":"Antengene Announces First Patient Dosed in Pivotal Phase Iii Clinch-3 Study of Atg-022","url":"https://stock-news.laohu8.com/highlight/detail?id=2669281133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669281133?lang=en_us&edition=fundamental","pubTime":"2026-09-21 08:30","pubTimestamp":1789950600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUAQF3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06996","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105922293","title":"ANTENGENE-B: THE CORE TRUST COMPANY LIMITED Acquires Shares, Long Position Rises to 10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105922293","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105922293?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:24","pubTimestamp":1789637091,"startTime":"0","endTime":"0","summary":"On September 14, 2026, Antengene Resurrection Limited, the nominee to the trustee of certain ESOP plan of ANTENGENE-B (wholly-owned by a subsidiary of THE CORE TRUST COMPANY LIMITED), was allotted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127541902","title":"ANTENGENE-B: TCT (BVI) Limited Acquires Shares, Long Position Rises to 10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127541902","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127541902?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:24","pubTimestamp":1789637070,"startTime":"0","endTime":"0","summary":"On September 14, 2026, Antengene Resurrection Limited, a nominee wholly-owned by TCT (BVI) Limited, was allotted and issued 10,090,000 new shares of ANTENGENE-B (06996). This share allotment...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134116943","title":"ANTENGENE-B: Sheng Tang Acquires Shares via Off-Exchange Derivatives, Long Position Rises to 0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134116943","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134116943?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:33","pubTimestamp":1789551203,"startTime":"0","endTime":"0","summary":"On September 10, 2026, Sheng Tang acquired 480,000 shares of ANTENGENE-B via an off-exchange derivative transaction (derivative instrument granting the right to purchase underlying shares). This is...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160608273","title":"ANTENGENE-B: Rafael Fonseca Acquires, Long Position Rises to 0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160608273","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160608273?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:24","pubTimestamp":1789550682,"startTime":"0","endTime":"0","summary":"On September 10, 2026, Rafael Fonseca increased his long position in ANTENGENE-B from 150,000 to 350,000 shares via an off-exchange derivative transaction (becoming holder of equity derivatives with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168286288","title":"ANTENGENE-B: Jing Qian Acquires, Long Position Rises to 0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168286288","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168286288?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:21","pubTimestamp":1789550502,"startTime":"0","endTime":"0","summary":"Jing Qian acquired an interest in equity derivatives over shares of ANTENGENE-B via an off-exchange derivative transaction on September 10, 2026. The acquisition was effected through equity...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863785","title":"Antengene Publishes Preclinical Study of ATG-037 Plus Selinexor in Multiple Myeloma in Cancer Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863785?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:27","pubTimestamp":1789360031,"startTime":"0","endTime":"0","summary":"Antengene publishes preclinical study of ATG-037 plus selinexor in multiple myeloma in Cancer Gene TherapyAntengene disclosed preclinical multiple myeloma data on ATG-037 combined with selinexor in a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL1CYShN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159433184","title":"Antengene-B Grants 11.52 Million RSUs to 75 Participants under 2022 Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1159433184","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159433184?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:43","pubTimestamp":1789044238,"startTime":"0","endTime":"0","summary":"Antengene Corporation Limited (Antengene-B) announced that on 10 September 2026 it granted a total of 11.52 million restricted share units (RSUs) under its 2022 RSU Scheme to 75 eligible...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169139997","title":"Antengene Caps August With Unchanged Share Count, Confirms Adequate Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1169139997","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169139997?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:10","pubTimestamp":1788426605,"startTime":"0","endTime":"0","summary":"Antengene Corporation Limited (Antengene) reported no change in its capital structure for the month ended 31 August 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662025552","title":"Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662025552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662025552?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:30","pubTimestamp":1787617800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUABJPBPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","06996","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179996720","title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179996720?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:04","pubTimestamp":1787612662,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170772290","title":"Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201","url":"https://stock-news.laohu8.com/highlight/detail?id=1170772290","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170772290?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:46","pubTimestamp":1787611595,"startTime":"0","endTime":"0","summary":"Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201482","title":"Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201482","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201482?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611365,"startTime":"0","endTime":"0","summary":"Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesAntengene secured Australian HREC clearance for its Phase 1 ATTRACT trial of ATG-201 in B-cell-mediat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL84Czw1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06996","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201488","title":"Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201488?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611362,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","06996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227355","title":"China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227355","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227355?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:44","pubTimestamp":1787564642,"startTime":"0","endTime":"0","summary":"China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growthOverviewChina biopharmaceutical firm's H1 revenue grew 55.5% yr/yr, driven by drug sales and collaborationsAdjusted net income ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","HK0000320223.HKD","BK1574","06996","BK1161","HK0000320264.USD","BK0239","02696","BK1191","HK0000165453.HKD","BK4139","BK1583","688428","BK1230","HK0000306685.HKD","00656","HK0000306701.USD","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","HCC","03160","PYZ","COAL","TM","BK4022","CR","ORR","BK4555","XAR","BK4187","LU2065731478.USD","IE0031619046.USD","BK4585","IE00B7SZL793.SGD","BK4588","LU0963586101.USD","BK1574","06996","BK4232","BK4604","BK4099","BK4006","BK1191","IE00B19Z4B17.USD","CRS","BK1583","IE00B66KJ199.SGD","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212911","title":"Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212911","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661212911?lang=en_us&edition=fundamental","pubTime":"2026-08-23 04:28","pubTimestamp":1787430511,"startTime":"0","endTime":"0","summary":"The market has spent the past week marking Antengene lower, with the stock down about 10% over seven days, yet the latest numbers tell a very different story. H1 2026 landed with a sharp swing into profit, with basic earnings per share at ¥0.34 and net income of ¥216.345 million on revenue of ¥513.076 million. For a high P/E stock trading at about 42.4x trailing earnings, this move into the black is the headline. The key question now is whether this profitability burst can justify that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VGFPF","BK1583","DECU","RGLO","VOTE","06996","BK1574","GXDW","BK1191","PMDE","JOYT","FEBU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0935},{"period":"3month","weight":0.0536},{"period":"6month","weight":-0.2468},{"period":"1year","weight":-0.4748},{"period":"ytd","weight":-0.066}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":-0.0354},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.0093},{"period":"1year","weight":-0.0477},{"period":"ytd","weight":-0.0212}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.014763},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.127204},{"month":7,"riseRate":0.333333,"avgChangeRate":0.018605},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.036567},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.023149},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"ANTENGENE-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ANTENGENE-B(06996),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ANTENGENE-B(06996) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ANTENGENE-B,06996,ANTENGENE-B股票,ANTENGENE-B股票老虎,ANTENGENE-B股票老虎国际,ANTENGENE-B行情,ANTENGENE-B股票行情,ANTENGENE-B股价,ANTENGENE-B股市,ANTENGENE-B股票价格,ANTENGENE-B股票交易,ANTENGENE-B股票购买,ANTENGENE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ANTENGENE-B(06996),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ANTENGENE-B(06996) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}